The cell therapy manufacturing market is estimated to reach close to USD 10 Billion by 2030,

Growing at an annualized rate of over 20%, the cell therapy manufacturing market is estimated to reach close to USD 10 Billion by 2030, claims Roots Analysis.
Spread the Word
Listed Under

* Market

* Research

* Babylon - New York - US

* Reports

BABYLON, N.Y. - Jan. 16, 2020 - PRLog -- The approval of KYMRIAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity

Roots Analysis has announced the addition of "Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030" report to its list of offerings.

Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry.

To order this 500+ page report, which features 160+ figures and 250+ tables, please visit this link

Key Market Insights

More than 160 organizations claim to be engaged in cell therapy manufacturing
The market landscape is dominated by industry players, representing more than 60% of the total number of stakeholders. Amongst these, over 55 are large or mid-sized firms (having more than 50 employees).

100+ players focused on T-cell and stem cell therapies
Most of these players are focused on manufacturing T-cell therapies, including CART, TCR or TILs. It is worth highlighting that more than 35 organizations claim to have necessary capabilities for the manufacturing of both types of therapies.

Presently, 70+ companies have commercial scale capacity
As majority of the cell therapy products are in clinical trials, the demand is high at this scale. However, it is worth noting that several players (~50%) have already developed commercial scale capacity for cell therapies.

Europe is currently considered a current hub for cell therapy production
More than 220 manufacturing facilities have been established by various players, worldwide; of these, 35% are in Europe, followed by those based in North America. Other emerging regions include Australia, China, Japan, Singapore, South Korea and Israel.

To request a sample copy / brochure of this report, please visit this link (

For additional details, please visit
or email (

You may also be interested in the following titles:

• Cell and Advanced Therapies Supply Chain Management Market, 2019-2030 (
• RNAi Therapeutics Market (2nd Edition), 2019 – 2030 (

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091 (

Media Contact
Roots Analysis
Location:Babylon - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Roots Analysis News
Most Viewed
Daily News

Like PRLog?
Click to Share